Send to a Friend Share

Oppenheimer Upgrades Cubist Pharmaceuticals (CBST) to Perform

October 29, 2009 7:47 AM EDT
CBST Hot Sheet
Rating Summary:
    6 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 12 | Down: 5 | New: 9
Oppenheimer upgrades Cubist Pharmaceuticals (Nasdaq: CBST) from Underperform to Perform. Price target $17.

To see more analyst ratings on CBST Click Here.

Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.

You May Also Be Interested In


Related Categories

Upgrades

Add Your Comment





Follow StreetInsider.com On Twitter